Harvard Medical School

Medical school in boston, ma

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.




Further reading


Documentaries, videos and podcasts





June 8, 2021
/PRNewswire/ -- Hosted by OrigiMed, the 4th OrigiMed International Summit was held in Shanghai under the guidance of the Shanghai Science and Technology...
Continental Who's Who
June 7, 2021
/PRNewswire/ -- Daphne E. Schneider MD is being recognized by Continental Who's Who as a Top Geriatrician in the field of Medicine for her exceptional...
June 3, 2021
Braintale, an innovative French company dedicated to neurological disorders and management of brain injured patients with its portfolio of solutions in neurology and intensive care, announces the appointment of Professor Spyros Artavanis-Tsakonas and doctor Nitza Thomasson to its board of directors.
William A. Haseltine
May 25, 2021
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
May 25, 2021
SAB to guide company's rapid development of differentiated therapeutics and vaccines to address a range of respiratory diseases including COVID-19
AuraVax Therapeutics Inc.
May 25, 2021
/PRNewswire/ -- AuraVax Therapeutics, Inc. (Auravax), a biotech company developing novel intranasal therapeutics and vaccines to help patients defeat...
Angus Liu
May 20, 2021
Recent research suggests that microorganisms living in the human gut may play a role in diseases ranging from obesity to cancer. A team at Harvard Medical School has gone one step further, linking the microbiome's genetic features to multiple diseases.
Mind Cure Health Inc.
May 19, 2021
/PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for...
Aesop Technology
May 18, 2021
/PRNewswire/ -- Researchers at Harvard Medical School, Brigham and Women's Hospital, Taipei Medical University, and Aesop Technology, a Taiwan-based startup,...
May 10, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors.
May 7, 2021
Xenter, Inc. Appoints Industry Leaders Robert S. Langer, Elazer R. Edelman, David J. Bearss and Mark Stautberg to Board of Directors; Closes $12M Series A - read this article along with other careers information, tips and advice on BioSpace
Dave Muoio
May 6, 2021
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please submit the good news--or the bad--from your shop, and we will feature it here at the end of each week.
Science X staff
May 5, 2021
An Austrian-American research team (University of Vienna, Department Evolutionary Anthropology and Harvard Medical School, Department of Genetics), in collaboration of Hungarian experts from Eötvös Loránd University, has developed a new method that allows the almost non-destructive extraction of genetic material from archeological human remains. The method allows anthropologists, archeologists and archaeogeneticists to avoid the risk of serious damage to artifacts of significant scientific and heritage value, which can then be fully examined in future research.
May 4, 2021
Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures.
The Aesthetic Society
May 3, 2021
/PRNewswire/ -- The Aesthetic Society announced the election of William P. Adams Jr. MD, a plastic surgeon practicing in Dallas, TX as the new President of the...
Zhang, J., Cai, Y., Xiao, T., Lu, J., Peng, H., Sterling, S. M., Walsh, R. M., Rits-Volloch, S., Zhu, H., Woosley, A. N., Yang, W., Sliz, P., Chen, B.
April 30, 2021
Throughout the COVID-19 pandemic, epidemiologists have monitored the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with particular focus on the spike protein. An early variant with an aspartic acid (D) to glycine (G) mutation at position 614, D614G, rapidly became dominant and is maintained in current variants of concern. Zhang et al. investigated the structural basis for the increased spread of this variant, which does so even though it binds less tightly to the host receptor (see the Perspective by Choe and Farzan). Structural and biochemical studies on a full-length G614 spike trimer showed that there are interactions not present in D614 that prevent premature loss of the S1 subunit that binds angiotensin-converting enzyme 2. This stabilization effectively increases the number of spikes that can facilitate infection. Science , this issue p. [525][1]; see also p. [466][2] Substitution for aspartic acid (D) by glycine (G) at position 614 in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to facilitate rapid viral spread. The G614 strain and its recent variants are now the dominant circulating forms. Here, we report cryo-electron microscopy structures of a full-length G614 S trimer, which adopts three distinct prefusion conformations that differ primarily by the position of one receptor-binding domain. A loop disordered in the D614 S trimer wedges between domains within a protomer in the G614 spike. This added interaction appears to prevent premature dissociation of the G614 trimer--effectively increasing the number of functional spikes and enhancing infectivity--and to modulate structural rearrangements for membrane fusion. These findings extend our understanding of viral entry and suggest an improved immunogen for vaccine development. [1]: /lookup/doi/10.1126/science.abf2303 [2]: /lookup/doi/10.1126/science.abi4711
April 28, 2021
Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately.
April 27, 2021
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced the appointment of Joanne M. Donovan, M.D., Ph.D., to the position of Chief Medical Officer
April 26, 2021
Danaher Announces Renowned Scientists To Join New Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace
April 26, 2021
Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, today announced the expansion of the company's Scientific Advisory Board (SAB) with the addition of Debora Marks, Ph.D., of Harvard Medical School and the Broad Institute, and Nicole Paulk, Ph.D., of the University of California San Francisco
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.